JP2023517729A - Ｔａａｒ１アゴニストの塩形態および結晶形態 - Google Patents

Ｔａａｒ１アゴニストの塩形態および結晶形態 Download PDF

Info

Publication number
JP2023517729A
JP2023517729A JP2022555821A JP2022555821A JP2023517729A JP 2023517729 A JP2023517729 A JP 2023517729A JP 2022555821 A JP2022555821 A JP 2022555821A JP 2022555821 A JP2022555821 A JP 2022555821A JP 2023517729 A JP2023517729 A JP 2023517729A
Authority
JP
Japan
Prior art keywords
disorders
methyl
ethyl
pyrazole
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022555821A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021185878A5 (https=
JP2023517729A5 (https=
Inventor
グレーザー，キルステン・アンドレア
シュヴィッター，ウルス
シュトヴァッサー，フランク
ティクセロン，フロランス・ニコル・アントワネット
トリュサルディ，レネ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of JP2023517729A publication Critical patent/JP2023517729A/ja
Publication of JPWO2021185878A5 publication Critical patent/JPWO2021185878A5/ja
Publication of JP2023517729A5 publication Critical patent/JP2023517729A5/ja
Priority to JP2025132332A priority Critical patent/JP2025166092A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2022555821A 2020-03-19 2021-03-17 Ｔａａｒ１アゴニストの塩形態および結晶形態 Pending JP2023517729A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025132332A JP2025166092A (ja) 2020-03-19 2025-08-07 Ｔａａｒ１アゴニストの塩形態および結晶形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20164069 2020-03-19
EP20164069.5 2020-03-19
PCT/EP2021/056749 WO2021185878A1 (en) 2020-03-19 2021-03-17 Salts and crystalline forms of a taar1 agonist

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025132332A Division JP2025166092A (ja) 2020-03-19 2025-08-07 Ｔａａｒ１アゴニストの塩形態および結晶形態

Publications (3)

Publication Number Publication Date
JP2023517729A true JP2023517729A (ja) 2023-04-26
JPWO2021185878A5 JPWO2021185878A5 (https=) 2024-03-26
JP2023517729A5 JP2023517729A5 (https=) 2024-03-26

Family

ID=69846246

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022555821A Pending JP2023517729A (ja) 2020-03-19 2021-03-17 Ｔａａｒ１アゴニストの塩形態および結晶形態
JP2025132332A Pending JP2025166092A (ja) 2020-03-19 2025-08-07 Ｔａａｒ１アゴニストの塩形態および結晶形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025132332A Pending JP2025166092A (ja) 2020-03-19 2025-08-07 Ｔａａｒ１アゴニストの塩形態および結晶形態

Country Status (13)

Country Link
US (1) US20230120311A1 (https=)
EP (1) EP4121428B1 (https=)
JP (2) JP2023517729A (https=)
KR (1) KR20220155575A (https=)
CN (1) CN115279752A (https=)
AU (1) AU2021238632A1 (https=)
BR (1) BR112022016746A2 (https=)
CA (1) CA3166331A1 (https=)
ES (1) ES3044409T3 (https=)
IL (1) IL294301A (https=)
MX (1) MX2022010794A (https=)
TW (1) TWI874616B (https=)
WO (1) WO2021185878A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023323858A1 (en) * 2022-08-12 2024-11-21 F. Hoffmann-La Roche Ag Pharmaceutical compositions comprising 5-ethyl-4-methyl- n-[4-[(2 s) morpholin-2-yl]phenyl]-1h-pyrazole-3-carboxamide
WO2024222860A1 (zh) * 2023-04-28 2024-10-31 江苏豪森药业集团有限公司 一种吗啉杂环类化合物的盐及其制备方法和应用
CN117903050B (zh) * 2024-03-15 2024-05-17 中国药科大学 阿立哌唑共晶及其药物组合物和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019512469A (ja) * 2016-03-17 2019-05-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｔａａｒのアゴニストとしての活性を有する５−エチル−４−メチル−ピラゾール−３−カルボキサミド誘導体

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019512469A (ja) * 2016-03-17 2019-05-16 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｔａａｒのアゴニストとしての活性を有する５−エチル−４−メチル−ピラゾール−３−カルボキサミド誘導体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
浅原 照三, 溶剤ハンドブック, JPN6011026738, 1985, pages 47 - 51, ISSN: 0005697098 *
長瀬博監訳, 最新 創薬化学 下巻, JPN6008054607, 25 September 1999 (1999-09-25), pages 347 - 365, ISSN: 0005697097 *
高田則幸: "創薬段階における原薬Formスクリーニングと選択", PHARM STAGE, vol. 6, no. 10, JPN6009053755, 15 January 2007 (2007-01-15), pages 20 - 25, ISSN: 0005697096 *

Also Published As

Publication number Publication date
CA3166331A1 (en) 2021-09-23
EP4121428A1 (en) 2023-01-25
BR112022016746A2 (pt) 2022-10-11
WO2021185878A1 (en) 2021-09-23
KR20220155575A (ko) 2022-11-23
US20230120311A1 (en) 2023-04-20
EP4121428B1 (en) 2025-08-13
IL294301A (en) 2022-08-01
AU2021238632A1 (en) 2022-07-14
TW202140466A (zh) 2021-11-01
ES3044409T3 (en) 2025-11-26
EP4121428C0 (en) 2025-08-13
TWI874616B (zh) 2025-03-01
CN115279752A (zh) 2022-11-01
MX2022010794A (es) 2022-09-27
JP2025166092A (ja) 2025-11-05

Similar Documents

Publication Publication Date Title
JP2025166092A (ja) Ｔａａｒ１アゴニストの塩形態および結晶形態
JP6995043B2 (ja) リジン特異的デメチラーゼ－１の阻害剤を含む組成物
AU2021200314B2 (en) Crystalline compounds
JP2014533719A (ja) アプレピタントｌ−プロリン溶媒和化合物−組成物及び共結晶
EP2496079A1 (en) Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide
JP7162964B2 (ja) 化合物の塩及びその結晶形態
JP2024517608A (ja) 結晶性カルバゾール誘導体
WO2022043755A2 (en) Crystalline edg-2 receptor antagonist and methods of making
JP2025528904A (ja) Ｔｙｋ２阻害剤およびその使用
HK40074347A (en) Salts and crystalline forms of a taar1 agonist
US12030886B2 (en) Form of ponatinib
US9266822B2 (en) Solid forms of tacedinaline
WO2020191140A1 (en) Co-crystal forms of selinexor
EP4553078A1 (en) 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-one and crystal of salt thereof
WO2012003413A1 (en) Novel solid forms of tacedinaline
JP2025527600A (ja) グルコシルセラミド合成酵素阻害薬の結晶形及びその使用
TW202506661A (zh) 一種酪氨酸激酶抑制劑的可藥用鹽、結晶形式及其製備方法
KR20250152557A (ko) 결정질 카바졸 유도체 및 이의 제조 방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240313

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241119

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20250408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250807